Holen Sie sich die Stockscreener-App
3.21
2.72%
0.085
Handel nachbörslich:
3.44
0.23
+7.17%
Schlusskurs vom Vortag:
$3.125
Offen:
$3.18
24-Stunden-Volumen:
8,216
Relative Volume:
0.51
Marktkapitalisierung:
$114.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+10.85%
1M Leistung:
+5.25%
6M Leistung:
+34.31%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.12
$3.2799
1-Wochen-Bereich:
$2.845
$3.2799
52-Wochen-Spanne:
$2.20
$4.08
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Firmenname
Eupraxia Pharmaceuticals Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie EPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
3.21 | 114.35M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 120.86B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 77.62B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.62B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Aktie (EPRX) Neueste Nachrichten
Knee Osteoarthritis Pipeline 2024: Key Companies, MOA, ROA, - openPR
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Stock Price Down 3.5% – Time to Sell? - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 3.5%Here's Why - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 3.5% – Here’s What Happened - Defense World
Eupraxia Pharmaceuticals Inc - Stockhouse Publishing
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Up 1.7% – Still a Buy? - Defense World
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Sees Significant Increase in Short Interest - Defense World
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Sees Significant Growth in Short Interest - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 1% – Should You Sell? - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 1%Here's Why - MarketBeat
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Stock Price Down 3.3% – What’s Next? - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) & Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Financial Analysis - Defense World
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases - The Eastern Progress Online
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Re - GuruFocus.com
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brok - GuruFocus.com
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online
Eupraxia Pharmaceuticals Strengthens Senior Management Team - GuruFocus.com
Eupraxia Pharmaceuticals Inc (EPRX-Q) QuotePress Release - The Globe and Mail
Eupraxia Pharma Shares Jump Following Data From Eosinophilic Esophagitis Trial - MarketWatch
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months - The Malaysian Reserve
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Re - GuruFocus.com
Eupraxia Pharmaceuticals Inc (EPRX-T) QuotePress Release - The Globe and Mail
Eupraxia Pharmaceuticals to Present at American College of Rheum - GuruFocus.com
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated at Rodman & Renshaw - Defense World
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Eupraxia Pharmaceuticals files report with SEC - Investing.com
Eupraxia Pharmaceuticals files report with SEC By Investing.com - Investing.com Australia
RODMAN&RENSHAW Upgrades Eupraxia Pharmaceuticals (NASDAQ:EPRX) to "Strong-Buy" - MarketBeat
Rodman & Renshaw rates Eupraxia stock Buy on 'groundbreaking delivery tech' - Investing.com Canada
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 - Canada NewsWire
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting - BioSpace
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Now Covered by Rodman & Renshaw - MarketBeat
Eupraxia Pharmaceuticals reports regulatory update - Investing.com
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 – Company AnnouncementFT.com - Financial Times
Newswire - KelownaNow
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - The Malaysian Reserve
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results – Company Announcement - Financial Times
Finansavisen - Finansavisen
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 5.4%What's Next? - MarketBeat
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results - Yahoo Finance
Troutman Pepper Advises Eupraxia Pharmaceuticals in Closing of a Non-Brokered Private Placement - Troutman Pepper
Eupraxia Pharmaceuticals Shares Rise After Completing Private Placement - MarketWatch
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million - Quantisnow
Eupraxia Pharmaceuticals Inc. - Baystreet.ca
Fennec Pharmaceuticals Inc. - Baystreet.ca
Stocks in play: Eupraxia Pharmaceuticals Inc. - Barchart
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 - Quantisnow
Finanzdaten der Eupraxia Pharmaceuticals Inc-Aktie (EPRX)
Es liegen keine Finanzdaten für Eupraxia Pharmaceuticals Inc (EPRX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):